Journals / Uluslararası Hematoloji-Onkoloji Dergisi / 2016 / Cilt: 26 - Sayı: 3

Primer Kemik Ve Yumuşak Doku Tümörlü Olgularımızın Klinik Ve Demografik Özellikleri

The Clinical and Demographic Characteristics of Our Cases with Primary Bone Tumors and Soft Tissue Tumors

Pages
159–166
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The overall survival and progression-free survival also did not differ significantly between the primary bone tumors and soft tissue tumors (p= 0.65).

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The current study aimed to investigate the clinical and demographic characteristics of the patients with sarcoma who were treated and followed-up in Dicle University Medical Oncology Department.
📊
Key Findings & Data:We retrospectively investigated the medical records of 547 patients who were diagnosed with sarcoma in the Dicle University School of Medicine, Department of Medical Oncology, between 2007 and 2015.
💡
Conclusion & Impact:The overall survival and progression-free survival also did not differ significantly between the primary bone tumors and soft tissue tumors (p= 0.65).
🔬Design:Research Article
📍Scope:2007 Verileri
⚙️Variables:Domain Parameters

Abstract

The current study aimed to investigate the clinical and demographic characteristics of the patients with sarcoma who were treated and followed-up in Dicle University Medical Oncology Department. We retrospectively investigated the medical records of 547 patients who were diagnosed with sarcoma in the Dicle University School of Medicine, Department of Medical Oncology, between 2007 and 2015. When we considered the total number of patients (total 23,264) admitted to our center between 2007 and 2015, the rate of our patients with sarcoma was found to be 2.3% of this total number. Primary bone tumor and soft tissue sarcoma were determined in 32% (n=172) and 68% (n=375) of the patients, respectively. The most frequent histological type was osteosarcoma. The age, location of the primary tumor, adjuvant chemotherapy, location of relapse (local, metastatic), history of smoking, and comorbid diseases showed statistically significant differences between two groups. The overall survival and progression-free survival also did not differ significantly between the primary bone tumors and soft tissue tumors (p= 0.65). The rate of our patients with sarcoma was 2.3% of the total number of patients (total 23,264) admitted to our center. This rate is higher than that in the literature.It is hard to interpret the results of the study, however it has been confirmed that the soft tissue sarcomas and primary bone tumors differ with regard to the age at diagnosis, location of tumor, location of relapse, prevalence of adjuvant chemotherapy and risk factors.

Özet

Merkezimizde takip ve tedavi edilmiş olan sarkom hastalarının klinik ve demografik özelliklerini araştırmak amaçlanmıştır. Dicle Üniversitesi Tıp Fakültesi Tıbbi Onkoloji Bilim Dalında 2007-2015 yılları arasında sarkom tanısı alan 547 hastanın dosyaları retrospektif olarak incelendi. Sarkoma hastalarımızın sayısı,2007-2015 tarihleri arasında merkezimize başvuran tüm kanser hastalarınının sayısına(toplam: 23.264) oranlandığında,saptadığımız değer %2.3 idi. Hastaların %32'si(n:172) primer kemik tümörü %68'i (n: 375) yumuşak doku sarkomu idi. En sık görülen histolojik tip, osteosarkom %14.5 (n:79). Yaş ,primer tümör yerleşim yeri, adjuvan kemoterapi, nüks yeri (lokal, metastatik),sigara öyküsü ve komorbid hastalıklar gibi parametreler açısından her iki grup arasında istatistiksel olarak anlamlı farklılık saptandı. Yumuşak doku tümörleri ve primer kemik tümörleri arasında tüm survival ve progresyonsuz survival açısından anlamlı farklılık saptanmadı (p: 0.65). Sarkoma tanılı hastalarımız, merkezimize başvuran tüm hastaların %2.3 idi. Bu oran literature verilerine göre daha yüksek bir değerdi. Sarkomların çok farklı histolojik subtipleri içermesi nedeniyle çalışma sonuçlarının yorumlanması güç olmakla birlikte yumuşak doku sarkomu ve primer kemik tümörleri arasında tanı yaşı,tümör yerleşim yeri, nüks yeri, adjuvan kemoterapi yaygınlığı ve risk faktörleri açısından da farklılıkların olduğu doğrulandı.

🔖

Cite This Article

ORUC, Z., KAPLAN, M. A., YERLİKAYA, H., CELIK, M. A., ORUC, I., URAKÇI, Z., KÜÇÜKÖNER, M., IŞIKDOĞAN, A. (2016). Primer Kemik Ve Yumuşak Doku Tümörlü Olgularımızın Klinik Ve Demografik Özellikleri. Uluslararası Hematoloji-Onkoloji Dergisi, Cilt: 26 - Sayı: 3, 159–166. https://ajindex.com/articles/322822

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Reichardt P. Soft tissue saromas,a look into the future:different treatments for different subtypes. Future Oncol 10: (8 Suppl) 19-27, 2014.
  2. Verweij J, Baker LH. Future treatment of soft tissue sarcomas will be driven by histological subtype and molecular aberra- tions. Eur J Cancer 46: 863-868, 2010.
  3. Lahat G, Lazar A, Lev D. Sarcoma epidemiology and etiology:potential environmental and genetic factors.Surg Clin North Am 88: 451-481, 2008. A Snapshot of Sarcoma. National Cancer Institute. Sept 2010.http//www.cancer.gov/aboutnci/servingpeople/can- cer-statistics/snapshots B Burningham Z, Hashibe M, Spector L, Schiffman J. The Epi- demiology of Sarcoma. Clinical Sarcoma Res 2: 14, 2012.
  4. TR. Ministry of Health, Directorate of Cancer Control Admin- istration: Evaluation of Cancer Reports (2009). http://www. iccp-portal.org/sites/default/files/plans/TurkeyNATIONAL_ CANCER_PROGRAM2-1.pdf (Access Date:01/10/2015)
  5. Surveillance, Epidemology and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence- SEER 9 Regs Research Data. http://seer.cancer.gov/ csr/1975_2009/ (Access Date 04/09/2015). In Cancer Incidence in Five Continents, Volume IX. IARC Sci- entific Publications No.160. Edited by Curado MP, Edwards B. Shin HR, Storm H. Ferlay J, HeanueM, Boyle P. Lyon: IARC; 2007. https://www.iarc.fr/en/publications/pdfs-online/ epi/sp160/CI5vol9-A.pdf (Access Date:01/10/2015)
  6. Mastrangelo G, Coindre JM, Ducimetriere F, et al. Incidence of soft tissue sarcoma and beyond:a population-based pro- spective study in 3 European regions.Cancer 118: 5339- 5348, 2012.
  7. Yücetürk G, Sabah D, Keçeci B, et al. Prevalence of bone and soft tissue tumors. Acta Orthop Traumatol Turc 45: 135-43, 2011.
  8. Kösem M, Bayram I. Distribution and Evaluation of Bone and Soft Tissue Tumors in Extremities in the Region of Van. Medi- cal Journal of Van 8: 93-96, 2001.
  9. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Sta- tistics Review, 1975-2008. National Cancer Instute. http:// seer.cancer.gov/archive/csr/1975_2011/ (Access Date 04/09/2015).
  10. Pukkala E, Martinsen JI, Lynge E, et al.Occupation and can- cer -follow up of 15 million people in five Nordic countries. Acta Oncol 48: 646-790, 2009.
  11. Wingren G, Frendrikson M, Brage HN, Nordenskjöld B, Ax- elson O. Soft tissue sarcoma and occupational exposures. Cancer 66: 806-811, 1990.
  12. Zahm SH, Blair A, Holmes FF, et al. A case-control study of soft tissue sarcoma. Am J Epidemiol 130: 665-674, 1989.
  13. Serraino D, Franceschi S, Talamini R,